Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ALNY
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Charles Elliott Sigal Director | ALNY Alnylam Pharmaceuticals, Inc. | Buy | 1,600 | $152.25 | $243.6K Buy | Form 4 ↗ |
| Nov 9, 2026 | Amy W. Schulman Director | ALNY Alnylam Pharmaceuticals, Inc. | Buy | 1,910 | $156.82 | $299.5K Buy | Form 4 ↗ |
| Jun 1, 2026 | David E. I. Pyott Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 17 | $302.65 | $5,145 Sale | Form 4 ↗ |
| Jun 1, 2026 | David E. I. Pyott Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 495 | $300.72 | $148.9K Sale | Form 4 ↗ |
| Jun 1, 2026 | David E. I. Pyott Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 1,222 | $299.87 | $366.4K Sale | Form 4 ↗ |
| Jun 1, 2026 | David E. I. Pyott Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 1,175 | $298.91 | $351.2K Sale | Form 4 ↗ |
| Jun 1, 2026 | David E. I. Pyott Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 921 | $297.71 | $274.2K Sale | Form 4 ↗ |
| Apr 6, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 199 | $333.94 | $66.5K Sale | Form 4 ↗ |
| Apr 6, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 293 | $331.89 | $97.2K Sale | Form 4 ↗ |
| Apr 6, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 829 | $330.46 | $274.0K Sale | Form 4 ↗ |
| Apr 6, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 909 | $329.76 | $299.8K Sale | Form 4 ↗ |
| Apr 6, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 56 | $320.14 | $17.9K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 8 | $325.49 | $2,604 Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 81 | $323.64 | $26.2K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 245 | $322.86 | $79.1K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 224 | $321.64 | $72.0K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 147 | $320.62 | $47.1K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 86 | $319.69 | $27.5K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 209 | $318.47 | $66.6K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 359 | $317.44 | $114.0K Sale | Form 4 ↗ |
| Apr 2, 2026 | Melissa McLaughlin Chief Human Resources Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 265 | $316.61 | $83.9K Sale | Form 4 ↗ |
| Mar 5, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 500 | $326.08 | $163.0K Sale | Form 4 ↗ |
| Mar 5, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 510 | $324.59 | $165.5K Sale | Form 4 ↗ |
| Mar 5, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 740 | $323.55 | $239.4K Sale | Form 4 ↗ |
| Mar 5, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 654 | $322.33 | $210.8K Sale | Form 4 ↗ |
| Mar 5, 2026 | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 153 | $326.24 | $49.9K Sale | Form 4 ↗ |
| Mar 5, 2026 | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 148 | $324.60 | $48.0K Sale | Form 4 ↗ |
| Mar 5, 2026 | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 233 | $323.25 | $75.3K Sale | Form 4 ↗ |
| Mar 5, 2026 | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 124 | $321.81 | $39.9K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 208 | $325.67 | $67.7K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 272 | $324.88 | $88.4K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 767 | $323.84 | $248.4K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 350 | $323.01 | $113.1K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 289 | $321.82 | $93.0K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 215 | $320.81 | $69.0K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 102 | $320.01 | $32.6K Sale | Form 4 ↗ |
| Mar 4, 2026 | Pushkal Garg EVP Chief R&D | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 106 | $319.03 | $33.8K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 265 | $325.67 | $86.3K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 345 | $324.88 | $112.1K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 973 | $323.84 | $315.1K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 444 | $323.01 | $143.4K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 368 | $321.82 | $118.4K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 274 | $320.81 | $87.9K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 129 | $320.01 | $41.3K Sale | Form 4 ↗ |
| Mar 4, 2026 | Yvonne Greenstreet Chief Executive Officer, Director | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 135 | $319.03 | $43.1K Sale | Form 4 ↗ |
| Mar 4, 2026 | Jeffrey V. Poulton EVP, Chief Financial Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 223 | $325.67 | $72.6K Sale | Form 4 ↗ |
| Mar 4, 2026 | Jeffrey V. Poulton EVP, Chief Financial Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 291 | $324.88 | $94.5K Sale | Form 4 ↗ |
| Mar 4, 2026 | Jeffrey V. Poulton EVP, Chief Financial Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 818 | $323.84 | $264.9K Sale | Form 4 ↗ |
| Mar 4, 2026 | Jeffrey V. Poulton EVP, Chief Financial Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 374 | $323.01 | $120.8K Sale | Form 4 ↗ |
| Mar 4, 2026 | Jeffrey V. Poulton EVP, Chief Financial Officer | ALNY Alnylam Pharmaceuticals, Inc. | Sale | 309 | $321.82 | $99.4K Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances